New Research Consortium to Measure Progression of Alzheimer’s Disease
“A new international consortium of academic and industrial leaders in the field of Alzheimer’s Disease (AD) is pleased to announce the launch of “RADAR-AD” (Remote Assessment of Disease And Relapse – Alzheimer’s Disease). The collaborative research program aims to develop technologies that remotely identify and measure “digital biomarkers” to assess the progression of early AD. RADAR-AD is a three-and-a-half-year public-private partnership, sponsored by the Innovative Medicines Initiative (IMI), and led by King’s College London and Janssen Pharmaceutica N.V.
The RADAR-AD consortium kicked off the project in London on January 30th and 31st, with team members discussing the work at hand and how the project will move forward. Consortium partners shared their insights and how best to utilize everyone’s expertise across the entire project.
The ultimate goal of RADAR-AD is the development and validation of technology-enabled, quantitative and sensitive measures of functional decline in people with early stage AD. To achieve this, the consortium will select, and if needed, modify, the most relevant available devices that can sensitively measure early and clinically meaningful functional decline in people with AD. This will be done in close collaboration with patient organizations and regulators.
To be successful in the relatively short project period, RADAR-AD will build on the experience and assets developed in the RADAR-CNS project, such as the RADAR-base platform. The selected devices will be validated in a cross-sectional multicenter observational clinical study of 220 individuals across the AD spectrum. The close association with RADAR-CNS and ample experience with and availability of large-scale clinical data will allow RADAR-AD to leverage experience already gained from that consortium. The project will run from January 2019 to July 2022.”
Source: RADAR-AD
